Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

News Conference News PCR London Valves 2022

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

December 07, 2022

Real-World TEER Outcomes in Primary MR Make Gains, but Questions Remain

News Conference News PCR London Valves 2022

Real-World TEER Outcomes in Primary MR Make Gains, but Questions Remain

December 01, 2022

Earlier Interventions and Later Redos? ‘Mature’ TAVI Still Has Growing Pains

News Conference News PCR London Valves 2022

Earlier Interventions and Later Redos? ‘Mature’ TAVI Still Has Growing Pains

November 28, 2022

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

November 18, 2022

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

News Conference News AHA 2022

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

Michael O'Riordan

November 10, 2022

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

News Conference News AHA 2022

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

November 10, 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

News Conference News AHA 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

November 06, 2022

Early ECMO No Better Than Watch-and-Wait Approach in Cardiogenic Shock

News Conference News AHA 2022

Early ECMO No Better Than Watch-and-Wait Approach in Cardiogenic Shock

November 06, 2022

CAST-HF: Could Myocardial Shockwave During CABG Yield Cardiac Regeneration?

News Conference News EACTS 2022

CAST-HF: Could Myocardial Shockwave During CABG Yield Cardiac Regeneration?

October 12, 2022

No Benefit of LAA Ligation During HeartMate 3 Implantation: MOMENTUM 3

News Conference News HFSA 2022

No Benefit of LAA Ligation During HeartMate 3 Implantation: MOMENTUM 3

Yael L. Maxwell

October 07, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

Newest MitraClip Iteration Performs Well in the Real World: EXPAND G4

News Conference News TCT 2022

Newest MitraClip Iteration Performs Well in the Real World: EXPAND G4

Yael L. Maxwell

September 23, 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

PROTECTED TAVR: No Less Stroke With Embolic Protection, but Some See Hope

News Conference News TCT 2022

PROTECTED TAVR: No Less Stroke With Embolic Protection, but Some See Hope

September 17, 2022

Routine Functional Testing Unnecessary After Stenting: POST-PCI

News Conference News ESC 2022

Routine Functional Testing Unnecessary After Stenting: POST-PCI

Yael L. Maxwell

September 06, 2022

New ESC/ERS Pulmonary Hypertension Guidelines Urge Precise Diagnosis, Early Treatment

News Conference News ESC 2022

New ESC/ERS Pulmonary Hypertension Guidelines Urge Precise Diagnosis, Early Treatment

September 01, 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

News Conference News ESC 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

August 29, 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

August 27, 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.